Insight, China's Pharmaceutical Industry

Company Deals

AstraZeneca’s Alexion Secures Gene Therapy Portfolio in Deal with Pfizer

AstraZeneca’s rare disease unit, Alexion (AZ, NASDAQ: AZN), has signed a significant purchase and license...

Company

AstraZeneca’s H1 2023 Financials Show 4% YOY Revenue Growth, Oncology and R&I Drive Sales

Fineline Cube Jul 31, 2023

UK-based pharmaceutical giant AstraZeneca plc (AZ, NASDAQ: AZN) has announced its financial results for the...

Company

Sanofi Reports 3.3% YOY Sales Growth in Q2 2023, Driven by Vaccines and Dupixent

Fineline Cube Jul 31, 2023

France-based Sanofi (NASDAQ: SNY) has released its financial results for the second quarter of 2023,...

Company Drug

Huadong Medicine Receives NMPA Approval for Phase I Clinical Trial of DR10624 for Weight Management

Fineline Cube Jul 31, 2023

China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received approval from...

Policy / Regulatory

NMPA Seeks Public Input on Strengthening Supervision of Medical Device Contract Manufacturing

Fineline Cube Jul 31, 2023

The National Medical Products Administration (NMPA) is currently seeking public feedback on the “Opinions on...

Policy / Regulatory

China’s NHC Launches Trial Specifications for Clinical Decision Support Systems in Hospitals

Fineline Cube Jul 31, 2023

The National Health Commission (NHC) has issued a set of specifications for the application and...

Company Drug

Yingli Pharma’s YL-17231 Receives NMPA Approval for Clinical Trials in Advanced Solid Tumors

Fineline Cube Jul 31, 2023

US-based Yingli Pharma, a company dedicated to developing drugs for both the China and US...

Policy / Regulatory

NHSA Issues 2023 Guidelines: Enhancing Basic Medical Insurance and Major Illness Coverage

Fineline Cube Jul 31, 2023

The National Healthcare Security Administration (NHSA) has released the “Notice on Ensuring Basic Healthcare Security...

Company Drug

Akeso Biopharma Initiates Phase Ia/Ib Study for TIGIT mAb AK127 in Solid Tumors Combination Therapy

Fineline Cube Jul 28, 2023

China-based Akeso Biopharma (HKG: 9926) has announced the first patient enrollment in a Phase Ia/Ib...

Company Deals

ACROBiosystems Partners with OBiO Technology to Advance Cell and Gene Therapy

Fineline Cube Jul 28, 2023

ACROBiosystems Group (SHE: 301080) has announced a partnership with China-based gene therapy specialist OBiO Technology...

Company Deals

Lucence and Innovent Biologics Partner to Enhance Access to Cholangiocarcinoma Treatment in Hong Kong

Fineline Cube Jul 28, 2023

Singapore-based precision medicine specialist Lucence, with a presence in Suzhou, Hong Kong, and Palo Alto...

Company Medical Device

Beijing Balance Medical’s Transcatheter Valve System Enters China’s Innovative Device Review

Fineline Cube Jul 28, 2023

China’s Beijing Balance Medical Technology Co., Ltd (SHA: 688198) has announced that its transcatheter valve...

Company Drug

Eli Lilly’s Tirzepatide Demonstrates Up to 26.6% Weight Loss in Phase III Obesity Studies

Fineline Cube Jul 28, 2023

US pharmaceutical major Eli Lilly & Co., (NYSE: LLY) has released final results from two...

Policy / Regulatory

CDE Issues Guiding Principles for Natural History Research in Rare Disease Drug Development

Fineline Cube Jul 28, 2023

The Center for Drug Evaluation (CDE) has released the “Guiding Principles for Natural History Research...

Company Drug

Sino Biopharmaceutical Receives NMPA Approval for Biosimilar Herceptin for HER2+ Cancers

Fineline Cube Jul 28, 2023

Sino Biopharmaceutical Ltd (HKG: 1177) has announced that it has received market approval from the...

Policy / Regulatory

CDE Launches Technical Guidelines to Emphasize Patient-Centered Drug Clinical Trials

Fineline Cube Jul 28, 2023

The Center for Drug Evaluation (CDE) has released a series of Technical Guidelines that encompass...

Company Drug

Eli Lilly’s Donanemab Shows Significant Slowdown in Alzheimer’s Disease Progression in Phase III Study

Fineline Cube Jul 28, 2023

US pharmaceutical major Eli Lilly and Company (NYSE: LLY) has revealed the complete results of...

Company Drug

Jiangsu Simcere Pharmaceutical Receives NMPA Approval for Atopic Dermatitis Drug SIM0278

Fineline Cube Jul 28, 2023

China’s Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) has announced that it has received clinical...

Company Deals Policy / Regulatory

Pingshan District and Fosun Pharma Ink Strategic Deal to Boost Biomedical Industry

Fineline Cube Jul 28, 2023

The People’s Government of Pingshan District in Shenzhen has signed a cooperation framework agreement with...

Company Drug

CanSino Biotechnology Receives NMPA Approval for Tetanus Vaccine CS-2047

Fineline Cube Jul 28, 2023

China-based vaccines specialist CanSino Biotechnology Inc., (HKG: 6185) has announced that it has received clinical...

Insight, China's Pharmaceutical Industry

Thermo Fisher Scientific to Divest Microbiology Business to Astorg for $1.075 Billion – Strategic Portfolio Optimization

Aureka Biotechnologies Secures $35M Series A+ Financing to Advance AuraIDE Platform for Functional Antibody Design

Hangzhou’s Adcoris Licenses First-in-Class 5T4-Targeting ADC ACR246 to U.S. Biotech K2 Therapeutics in Deal Worth Up to $730 Million

Sino Biopharmaceutical’s Chia Tai Tianqing and Shanghai Reunion Partner to Commercialize Respacio Hydrogel for Cervical Cancer Radiotherapy Protection in China

Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets

AbbVie Submits FDA Filing for Skyrizi Subcutaneous Induction Therapy in Crohn’s Disease – Expanding IL-23 Inhibitor Franchise

GSK’s Efimosfermin Receives Dual Regulatory Designations for MASH Treatment – Breakthrough Therapy and PRIME Status Support Phase III Development

AstraZeneca’s Alexion Secures Gene Therapy Portfolio in Deal with Pfizer

AstraZeneca’s H1 2023 Financials Show 4% YOY Revenue Growth, Oncology and R&I Drive Sales

Sanofi Reports 3.3% YOY Sales Growth in Q2 2023, Driven by Vaccines and Dupixent

Huadong Medicine Receives NMPA Approval for Phase I Clinical Trial of DR10624 for Weight Management

NMPA Seeks Public Input on Strengthening Supervision of Medical Device Contract Manufacturing

China’s NHC Launches Trial Specifications for Clinical Decision Support Systems in Hospitals

Yingli Pharma’s YL-17231 Receives NMPA Approval for Clinical Trials in Advanced Solid Tumors

NHSA Issues 2023 Guidelines: Enhancing Basic Medical Insurance and Major Illness Coverage

Akeso Biopharma Initiates Phase Ia/Ib Study for TIGIT mAb AK127 in Solid Tumors Combination Therapy

ACROBiosystems Partners with OBiO Technology to Advance Cell and Gene Therapy

Lucence and Innovent Biologics Partner to Enhance Access to Cholangiocarcinoma Treatment in Hong Kong

Beijing Balance Medical’s Transcatheter Valve System Enters China’s Innovative Device Review

Eli Lilly’s Tirzepatide Demonstrates Up to 26.6% Weight Loss in Phase III Obesity Studies

CDE Issues Guiding Principles for Natural History Research in Rare Disease Drug Development

Sino Biopharmaceutical Receives NMPA Approval for Biosimilar Herceptin for HER2+ Cancers

CDE Launches Technical Guidelines to Emphasize Patient-Centered Drug Clinical Trials

Eli Lilly’s Donanemab Shows Significant Slowdown in Alzheimer’s Disease Progression in Phase III Study

Jiangsu Simcere Pharmaceutical Receives NMPA Approval for Atopic Dermatitis Drug SIM0278

Pingshan District and Fosun Pharma Ink Strategic Deal to Boost Biomedical Industry

CanSino Biotechnology Receives NMPA Approval for Tetanus Vaccine CS-2047

You Missed

AbbVie Submits FDA Filing for Skyrizi Subcutaneous Induction Therapy in Crohn’s Disease – Expanding IL-23 Inhibitor Franchise

GSK’s Efimosfermin Receives Dual Regulatory Designations for MASH Treatment – Breakthrough Therapy and PRIME Status Support Phase III Development

Prothena’s Coramitug Receives FDA Fast Track Designation for ATTR-CM – Advancing Novo Nordisk’s $1.2B Amyloidosis Pipeline

Jecho Biopharmaceuticals Secures FDA Clearance for JLM019 Clinical Study in Advanced Malignant Tumors – Novel Bispecific Fc Fusion Protein Targets “Cold Tumors”